For the quarter ending 2025-09-30, ANIK had $4,823K increase in cash & cash equivalents over the period. $4,983K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,329 | -8,843 |
| Depreciation | 1,391 | 2,663 |
| Amortization of acquisition related intangible assets | 12 | 345 |
| Non-cash operating lease cost | 495 | 1,067 |
| Impairment of long-lived assets | 0 | - |
| Stock-based compensation expense | 2,215 | 5,411 |
| Deferred income taxes | 3 | 15 |
| Provision for credit losses | 76 | 133 |
| Provision for inventory | 1,127 | 3,842 |
| Interest income on notes receivable | 79 | 345 |
| Gain on sale of assets | 451 | 505 |
| Accounts receivable | -1,294 | -659 |
| Inventories | 443 | -2,252 |
| Prepaid expenses, other current and long-term assets | -219 | -797 |
| Accounts payable | 231 | -1,066 |
| Operating lease liabilities | -480 | -1,045 |
| Accrued expenses, other current and long-term liabilities | 3,610 | -5,251 |
| Income taxes | -21 | -448 |
| Cash flows from investing activities | 6,870 | -319 |
| Proceeds from sale of parcus | 0 | 4,496 |
| Proceeds from sale of intangible assets | 0 | 600 |
| Notes receivable | 155 | 328 |
| Purchases of property and equipment | 1,887 | 4,291 |
| Acquisition of intangible assets | 0 | - |
| Net cash used in investing activities | -1,732 | 1,133 |
| Proceeds from employee stock purchase program | 0 | 261 |
| Cash paid for tax withheld on vested restricted stock awards | 13 | 1,549 |
| Proceeds from exercises of equity awards | 0 | 0 |
| Repurchases of common stock | 0 | 3,971 |
| Net cash used in financing activities | -13 | -5,259 |
| Exchange rate impact on cash | -302 | 453 |
| Decrease in cash and cash equivalents | 4,823 | -3,992 |
| Cash and cash equivalents at beginning of period | 57,159 | - |
| Cash and cash equivalents at end of period | 57,990 | - |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)